Speakers

Expand/Collapse

Arabella Young
Assistant Professor in the Department of Pathology; Investigator at the Huntsman Cancer Institute
The University of Utah

Day One

Wednesday May 11, 2022

9:40 am | Regulation of the Adenosinergic Pathway in the Tumor Microenvironment & In Response to Therapies

Bin Zhang
Professor
Northwestern University

Carine Paturel
Senior Director, Program & Portfolio Strategy
Innate Pharma

Day Two

Thursday May 12, 2022

3:45 pm | IPH5301, A Differentiated Therapeutic Antibody Targeting Membrance & Soluble CD73, Unleash Anti-Tumor Immune Response In Combination With Cancer Therapies

Daniel DiRenzo
Associate Director & Project Lead
Arcus Biosciences

Day Two

Thursday May 12, 2022

9:30 am | Dual A2aR/A2bR Antagonism with Etrumadenant Blocks the Immunosuppressive Effects of Adenosine & Enhances Anti-Tumor Immune Responses

Hui Zou
Chief Scientific Officer
Phanes Therapeutics

Day Two

Thursday May 12, 2022

11:15 am | Preclinical Studies of PT199, a Humanized mAb That Fully Inhibits Both Membrane Bound & Soluble Serum CD73

John Stagg
Professor
University of Montreal

Day One

Wednesday May 11, 2022

2:15 pm | Combining CD39 & CD73 Inhibition for Treatment of Pancreatic Cancer

Kavitha Yaddanapudi
Associate Professor
University of Louisville

Kris Sachsenmeier
Head, Oncology Translational Strategy: Cold-to-Hot
Takeda

Day One

Wednesday May 11, 2022

4:45 pm | Interactive Roundtable Discussions

Lara McGrath
Director, Translational Medicine
AstraZeneca

Maura Rosetti
Associate Director
iTeos Therapeutics

Michail Sitkovsky
Professor & Director
Northeastern University

Day One

Wednesday May 11, 2022

9:10 am | The Discovery of Biochemical & Immunological Mechanisms of the Hypoxia- A2-Adenosinergic Immunosuppression as the Foundation of the Conceptually Novel Immunotherapies of Cancer Using Several Classes of Anti-Hypoxia-A2- Adenosingergic Drugs

Musheng Bao
Senior Director
Harbour Biomed

Day Two

Thursday May 12, 2022

4:15 pm | HBM1007, A Fully Human CD73 Antibody With Allosteric Inhibition & Strong Internalization Mediated Target Downregulation For Cancer Therapy

Norihiro Nakamura
Chief Scientific Officer
BrightPath Biotherapeutics

Day Two

Thursday May 12, 2022

10:00 am | Targeted Inhibition of Adenosine-Pathway by Humanized Antibodies to Enhance the Cancer Immunity

Paul Beavis
Associate Professor
Peter MacCallum Cancer Center

Day One

Wednesday May 11, 2022

4:15 pm | Using a Novel Reporter Mouse to Investigate A2AR Expression Within the Tumor Microenvironment

Phil Darcy
Group Leader, Cancer Immunotherapy Laboratory
Peter MacCallum Cancer Centre

Day Two

Thursday May 12, 2022

11:45 am | Dual Blockade of Adenosine and PD-1 Immunosuppression Enhances Chimeric Antigen Receptor T-Cell Therapy

Pnina Fishman
Chief Executive Officer & Chief Scientific Officer
Can-Fite BioPharma

Day Two

Thursday May 12, 2022

2:45 pm | Targeting the A3 Adenosine Receptor for the Treatment of Advanced Liver Cancer

Rakesh Kumar
Global Project Leader
Astrazeneca

Day Two

Thursday May 12, 2022

9:00 am | Targeting the Adenosine-Pathway for Cancer Immunotherapy

Richard Miller
Chief Executive Officer
Corvus Pharmaceuticals

Day Two

Thursday May 12, 2022

2:15 pm | Mupadolimab: A B Cell Activating Anti-CD73 Antibody for Immunotherapy of Cancer & Viral Diseases

Robert Leone
Assistant Professor Medical Oncology
John Hopkins University School of Medicine

Sally Ross
Project Head
iTeos Therapeutics

Day One

Wednesday May 11, 2022

12:10 pm | Can Biomarkers Be Used to Identify Patients Who Are Most Likely to Benefit from Adenosine-Pathway Targeted Cancer Immunotherapy?

Sanez Yahyanejad
Associate Director R&D
InteRNA Technologies

Day Two

Thursday May 12, 2022

1:15 pm | INT-1B3 Effectively Modulates the Adenosine Cloud & Induces Immunogenic Cell Death in Preclinical Tumor Models: Opportunities for Translational Medicine

Simon Robson
Professor of Medicine & Anesthesiology
Harvard Medical School, Scientific Founder Purinomia

Day One

Wednesday May 11, 2022

1:45 pm | Targeting CD39 in Malignancy: Immunotherapy & Inhibition of Angiogenesis

Day Two

Thursday May 12, 2022

5:15 pm | Chair’s Closing Remarks

8:50 am | Chair’s Opening Remarks

Stephen Hatfield
Assistant Professor
Northeastern University

Day One

Wednesday May 11, 2022

10:10 am | Anti-hypoxia Treatments to Reprogram The Tumor Microenvironment & Improve Cancer Immunotherapies

Day Two

Thursday May 12, 2022

4:45 pm | Therapeutic Targeting of Hypoxia-A2-Adenosinergic Signaling to Improve the Outcomes Oxygen-Ventilated COVID-19 Patients

Susanta Samajdar
Senior Vice President and Head of Discovery
Aurigene Discovery Technologies Limited

Day One

Wednesday May 11, 2022

3:45 pm | Dual Targeting of CD73 & A2AR for Effective Suppression of Adenosine Signaling

Xavier Leroy
Chief Scientific Officer
Domain Therapeutics

Day One

Wednesday May 11, 2022

5:15 pm | Chair’s Closing Remarks

4:45 pm | Interactive Roundtable Discussions

1:40 pm | Chair’s Remarks

Yvonne McGrath
Chief Scientific Officer
iTeos Therapeutics

Zac Cooper
Director, Translational Medicine Lead
Astrazeneca

Day One

Wednesday May 11, 2022

9:00 am | Chair’s Opening Remarks